This inventor holds 2 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 2 EPO patents. Top assignees: Adocia, Catalent France Beinheim Sa, Endotis Pharma. Active years: 2012-2016.
Company Filing History:
1 out of 43 
1 out of 1 
1 out of 1 Years Active: 2012-2016
Title: Guy Dubreucq: Innovator in Pharmaceutical Formulations
Introduction
Guy Dubreucq is a notable inventor based in Lille, France. He has made significant contributions to the field of pharmaceutical formulations, particularly focusing on innovative oral dosage forms. With a total of 2 patents to his name, Dubreucq's work has the potential to impact therapeutic practices.
Latest Patents
Dubreucq's latest patents include a pharmaceutical oral dosage form containing a synthetic oligosaccharide. This invention concerns a formulation intended for oral administration that includes a synthetic oligosaccharide with therapeutic activity. The formulation is designed to optimize the delivery of the oligosaccharide, incorporating various components such as a lipophilic phase, surfactants, and optional hydrophilic solvents. Another significant patent is the complex polymer amphiphile-PDGF, which is characterized by its stability and water-solubility, featuring a hydrophilic polymeric backbone functionalized with hydrophobic substituents.
Career Highlights
Throughout his career, Dubreucq has worked with prominent companies in the pharmaceutical industry, including Adocia and Endotis Pharma. His experience in these organizations has allowed him to develop and refine his innovative ideas in drug formulation.
Collaborations
Dubreucq has collaborated with talented professionals in his field, including Latifa Dahri-Correia and Jose Correia. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Guy Dubreucq stands out as an influential inventor in the pharmaceutical sector, with a focus on innovative formulations that enhance therapeutic efficacy. His contributions continue to shape the landscape of drug delivery systems.